BAFNAPH — BAFNA Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapMomentum Trap

Annual income statement for BAFNA Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	R2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	851	1,154	1,526	1,460	1,506
Cost of Revenue
Gross Profit	339	389	497	471	527
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	808	1,035	1,454	1,405	1,404
Operating Profit	43.1	119	71.3	55	102
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	52.2	116	73.5	41.5	110
Provision for Income Taxes
Net Income After Taxes	52.2	113	73.5	41.5	111
Net Income Before Extraordinary Items
Net Income	52.2	113	73.5	41.5	111
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	52.2	113	73.5	41.5	110
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3.1	4.78	3.08	2.69	4.64